Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Biocept Inc

(NASDAQ: BIOC)
Add to Portfolio
-0.07 (-6.48%)
as of Jun 14, 2019

Last 1.01
Change -0.07 (-6.48%)
Open 1.07
Prev. Close 1.08
Today's Range
1.01
1.08
52wk Range
0.66
12.15
Volume 702,600
Avg Volume 10,053,030
Sector SIC-8071 Services-Medical Laboratories

Perfomance Comparison

Name Today 3-Month 1-Year
BIOC -6.48% -7.34% -85.97%
DJIA -0.07% -0.49% +3.63%
S&P 500 -0.16% +0.47% +3.76%

Key Statistics

Annual EPS -7.16
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 20,380
Weighted Alpha -89.80
Standard Deviation -0.41
Profit Margin 3.63%
Beta 2.17

Growth Rates

YTD +17.44%
1-Year -87.05%
3-Year -98.19%
5-Year -99.85%

Opinion

Sell Hold Buy

Recent Headlines

Biocept Announces Clinical Validation and Commercial

PR Newswire via COMTEX - Mon May 20, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the comm(full story)
BIOC: 1.01 (-0.07)

Biocept Reports First Quarter 2019 Financial Results

PR Newswire via COMTEX - Wed May 08, 04:05PM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the(full story)
BIOC: 1.01 (-0.07)

Biocept to Release First Quarter 2019 Financial

PR Newswire via COMTEX - Wed May 01, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve the outcomes of patients diagnose(full story)
BIOC: 1.01 (-0.07)

Biocept Reports 2018 Fourth Quarter and Full Year

PR Newswire via COMTEX - Thu Mar 28, 04:05PM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the(full story)
BIOC: 1.01 (-0.07)

Biocept Broadens Commercial Focus of its Target

PR Newswire via COMTEX - Tue Mar 26, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it (full story)
BIOC: 1.01 (-0.07)